15th World ADC San Diego 2024
Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and Astellas’ PADCEV, all alongside a frenzy of companies entering the field and billion-dollar partnerships and M&As from Pfizer, AbbVie, J&J, Merck, Genmab, Ipsen and beyond, ADCs have firmly positioned themselves at the forefront of oncology R&D and dealmaking.
Returning as industry’s definitive ADC forum from early discovery to late-phase manufacturing, the 15th World ADC San Diego (November 4-7, 2024 | San Diego, CA) is the world-leading, largest, and most comprehensive ADC-focused conference to maximize the therapeutic window of ADCs. Whether you have just ventured into the ADC space or are an ADC guru, you’ll leave this meeting with the insight and connections needed to overcome your challenges and make impactful strides in your work.
Gain exclusive access to the full event guide to view the full agenda with 120+ industry-leading speakers leading 6 end-to-end development content tracks:
- Discovery: Uncover cutting-edge developments in ADC payloads, linkers, and site-specific conjugation technologies to ride the tidal wave of ADC design and chemistry innovation with Heidelberg Pharma, Sutro Biopharma, and ADC Therapeutics
- Cellular Biology: Discover novel ADC target discovery and efficiently engineer antibody properties to elevate your ADC development for novel target and therapeutic applications with Innovent Biologics, Oxford BioTherapeutics, and SOTIO Biotech
- Translational: Evaluate ADC safety and efficacy characterization, and preclinical model selection and predictiveness to minimize the translational mismatch and supercharge successful ADC progression into the clinic with Daiichi Sankyo, AstraZeneca, and Genentech
- Clinical: Deep-dive into brand-new early and late-stage clinical data, contextualize clinical performance, and explore ADC dose escalation to best categorize what makes a clinically effective ADC with AbbVie, Ipsen, and Mythic Therapeutics
- Process & Analytical Development: Explore analytical characterization of ADC DAR and impurities, and learn to streamline drug-linker and conjugation process optimization to reinvigorate your ADC product quality with Mersana Therapeutics, BMS, and GlaxoSmithKline
- Manufacturing & Supply Chain: Understand ADC manufacturing risk management and scale-up, selection criteria for CDMO partners, and regulatory CMC strategy to equip you with robust and efficient manufacturing practices under accelerated ADC development timelines with Exelixis, Merck, and Pfizer
Access to the complete agenda here including an 8-tracked seminar day and 10 industry-beating workshops.
Don’t miss out on the chance to reunite with the antibody-drug conjugate community while reflecting on the exciting year that ADCs have had, and building momentum for the future of this innovative field.
